Inhibition of nitric oxide-stimulated vasorelaxation by carbon monoxide-releasing molecules

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 11, 2011, Pages 2570-2576

  Marazioti, Antonia ^a   Bucci, Mariarosaria ^b   Coletta, Ciro ^c   Vellecco, Valentina ^b   Baskaran, Padmamalini ^d   Szabó, Csaba ^c   Cirino, Giuseppe ^b   Marques, Ana Rita ^e   Guerreiro, Bruno ^e   Gonçalves, Ana M L ^e   Seixas, João D ^e   Beuve, Annie ^d,e   Romão, Carlos C ^f   Papapetropoulos, Andreas ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^e Alfama   (Portugal)

^f INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

Author keywords

carbon monoxide; cGMP; nitric oxide; pharmacology; vascular biology

Indexed keywords

CARBON MONOXIDE; CARBON MONOXIDE RELEASING MOLECULE; CYCLIC GMP; LUMINOL; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASODILATATION;

ANIMALS; AORTA; CARBON MONOXIDE; CELLS, CULTURED; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANYLATE CYCLASE; MALE; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; VASODILATION;

EID: 80054941639     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.229039     Document Type: Article

References (28)

1. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9:728-743.
2. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev. 2005;57: 585-630. (Pubitemid 43036442)
3. Ryter SW, Alam J, Choi AMK. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86: 583-650.
4. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, and Soares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med. 2000;192: 1015-1026.
5. Durante W, Schafer A. Carbon monoxide and vascular cell function (review). Int J Mol Med. 1998;2:155-262.
6. Szabo S. Gaseotransmitters: new frontiers for translational science. Sci Transl Med. 2010;2:59ps54.
7. Motterlini R, Mann BE, Johnson TR, Clark JE, Foresti R, Green CJ. Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. Curr Pharm Des. 2003;9:2525-2539. (Pubitemid 37236371)
8. Motterlini R, Foresti R, Green CJ. Studies on the development of carbon monoxide-releasing molecules: potential applications for the treatment of cardiovascular dysfunction. In: Wang R, ed. Carbon Monoxide and Cardiovascular Functions. Boca Raton, FL: CRC Press; 2002:249-271.
9. Foresti R, Hammad J, Clark JE, Johnson TR, Mann BE, Friebe A, Green CJ, Motterlini R. Vasoactive properties of CORM-3, a novel watersoluble carbon monoxide-releasing molecule. Br J Pharmacol. 2004;142: 453-460. (Pubitemid 38869858)
10. Motterlini R, Sawle P, Hammad J, Bains S, Alberto R, Foresti R, Green CJ. CORM-A1: a new pharmacologically active carbon monoxidereleasing molecule. FASEB J. 2005;19:284-286. (Pubitemid 40189283)
11. Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res. 2002;90:e17-e24.
12. Kharitonov VG, Sharma VS, Pilz RB, Magde D, Koesling D. Basis of guanylate cyclase activation by carbon monoxide. Proc Natl Acad Sci USA. 1995;92:2568-2571.
13. Lucas KA, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375-414.
14. Ahluwalia A, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ. Anti-inflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of pselectin expression and leukocyte recruitment. Proc Natl Acad Sci USA. 2004;101:1386-1391. (Pubitemid 38182698)
15. Moncada S, Higgs E. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
16. Papapetropoulos A, Marczin N, Mora G, Milici A, Murad F, Catravas JD. Regulation of vascular smooth muscle soluble guanylate cyclase activity, mRNA, and protein levels by cAMP-elevating agents. Hypertension. 1995;26:696-704.
17. Zhao H, Joseph J, Zhang H, Karoui H, Kalyanaraman B. Synthesis and biochemical applications of a solid cyclic nitrone spin trap: a relatively superior trap for detecting superoxide anions and glutathiyl radicals. Free Rad Biol Med. 2001;31:599-606. (Pubitemid 32777860)
18. Santos-Silva T, Mukhopadhyay A, Seixas JD, Bernardes GJL, Romão CC, Romão MJ, CORM-3 Reactivity toward proteins: the crystal structure of a Ru(II) dicarbonyl-lysozyme complex. J Am Chem Soc. 2011;133:1192-1195.
19. Obirai JC, Hamadi S, Ithurbide A, Wartelle C, Nyokong T, Zagal J, Top SaB, F. UV-visible and electrochemical monitoring of carbon monoxide release by donor complexes to myoglobin solutions and to electrodes modified with films containing hemin. Electroanalysis. 2006;18: 1689-1695.
20. Wang R, Wu L. The chemical modification of KCa channels by carbon monoxide in vascular smooth muscle cells. J Biol Chem. 1997;272: 8222-8226. (Pubitemid 27147775)
21. Lamothe M, Chang FJ, Balashova N, Shirokov R, Beuve A. Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site? Biochemistry. 2004;43:3039-3048.
22. Stone J, Marletta M. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem Biol. 1998;5:255-261. (Pubitemid 28259740)
23. Hoenicka M, Becker EM, Apeler H, Sirichoke T, Schröder H, Gerzer R, Stasch JP. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med. 1999;77:14-23. (Pubitemid 29146177)
24. Lamon BD, Zhang FF, Puri N, Brodsky SV, Goligorsky MS, Nasjletti A. Dual pathways of carbon monoxide-mediated vasoregulation: modulation by redox mechanisms. Circ Res. 2009;105:775-783.
25. Sayed N, Baskaran P, Ma X, Van den Akker F, Beuve A. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci USA. 2007;104:12312-12317. (Pubitemid 47206134)
26. Mosi R, Seguin B, Cameron B, Amankwa L, Darkes MC, Fricker SP. Mechanistic studies on AMD6221: a ruthenium-based nitric oxide scavenger. Biochem Biophys Res Commun. 2002;292:519-529. (Pubitemid 34694294)
27. Bencini A, Failli P, Valtancoli B, Bani D. Low molecular weight compounds with transition metals as free radical scavengers and novel therapeutic agents. Cardiovasc Hematol Agents Med Chem. 2010;8: 128-146.
28. Chatterjee D, Mitra A, Van Eldik R. Kinetics and mechanism of the reaction of [RuIII(edta)(H2O)]-with HOBr to form an intermediate RuVAO complex in aqueous solution. Dalton Trans. 2006:4691-4695. (Pubitemid 44522164)